HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N6022

inhibits S-nitrosoglutathione reductase; structure in first source

Networked: 15 relevant articles (2 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Rosenthal, Gary J: 6 articles (01/2014 - 05/2011)
2.	Singh, Avtar K: 5 articles (01/2021 - 01/2018)
3.	Singh, Inderjit: 5 articles (01/2021 - 01/2018)
4.	Richards, Jane P: 5 articles (01/2014 - 05/2011)
5.	Sun, Xicheng: 5 articles (01/2014 - 05/2011)
6.	Khan, Mushfiquddin: 4 articles (01/2021 - 12/2019)
7.	Qiao, Fei: 4 articles (01/2021 - 12/2019)
8.	Blonder, Joan P: 4 articles (01/2014 - 05/2011)
9.	Mutka, Sarah C: 4 articles (01/2014 - 05/2011)
10.	Qiu, Jian: 4 articles (01/2014 - 05/2011)

Related Diseases

1.	Stroke (Strokes) 12/01/2019 - "Neurovascular protection by GSNO/N6022 in both pre- and postischemic injury groups support GSNO as a promising drug candidate for the prevention and treatment of stroke injury." 01/01/2020 - "Based on the efficacy of N6022 in the stroke animal model and its use in human therapeutic studies without toxicity, we submit that GSNOR is a druggable target, and N6022 is a promising drug candidate for human stroke therapy." 01/01/2020 - "Because age is the major risk factor of stroke and recovery in aged stroke patients is low and slow, we investigated the efficacy of GSNOR inhibition using a GSNOR selective inhibitor N6022 in a clinically relevant middle-aged cerebral ischemia and reperfusion (IR) mouse model of stroke. "
2.	Infarction (Infarctions) 12/01/2019 - "eNOS-null mice had a higher degree (P< .05) of injury than WT. Pre- or postinjury treatment with either GSNO or N6022 significantly reduced infarct volume, improved neurological and sensorimotor function in both WT and eNOS-null mice. " 01/01/2020 - "N6022 (5 mg/kg; iv) treatment of IR mice at 2 h after reperfusion followed by the treatment of the same dose daily for 3 days reduced the infarct volume and decreased the neurological score. "
3.	Brain Infarction 01/01/2020 - "Daily treatment of IR animals with N6022 for 2 weeks significantly improved neurological score, brain infarctions/atrophy, survival rate, motor (measured by cylinder test) and cognitive (evaluated by novel object recognition test) functions which paralleled the decreased activity of GSNOR, reduced levels of peroxynitrite and decreased neurological score. "
4.	Brain Ischemia (Cerebral Ischemia) 01/01/2020 - "Because age is the major risk factor of stroke and recovery in aged stroke patients is low and slow, we investigated the efficacy of GSNOR inhibition using a GSNOR selective inhibitor N6022 in a clinically relevant middle-aged cerebral ischemia and reperfusion (IR) mouse model of stroke. "
5.	Atrophy 01/01/2020 - "Daily treatment of IR animals with N6022 for 2 weeks significantly improved neurological score, brain infarctions/atrophy, survival rate, motor (measured by cylinder test) and cognitive (evaluated by novel object recognition test) functions which paralleled the decreased activity of GSNOR, reduced levels of peroxynitrite and decreased neurological score. "

Related Drugs and Biologics

1.	Peroxynitrous Acid (Peroxynitrite)
2.	Oxidoreductases (Dehydrogenase)
3.	Methacholine Chloride (Methacholine)
4.	glutathione-independent formaldehyde dehydrogenase (formaldehyde dehydrogenase)
5.	Pyrroles
6.	S-Nitrosoglutathione
7.	Cytokines

Related Therapies and Procedures

1.	Therapeutics